Evidence map›Paper›PMID 25051439›Full record

ArticleEndocrinology2014

Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.

Shoji Ichikawa, Amie K Gray, Leah R Padgett, Matthew R Allen, Erica L Clinkenbeard, Nicole M Sarpa, Kenneth E White, Michael J Econs

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. GALNT3 in Ischemia-Reperfusion Injury of the Kidney.Journal of the American Society of Nephrology : JASN · 2025
    Article
  4. Runx2 RegulatesInternational journal of molecular sciences · 2024
    Article
  5. Review
  6. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  7. Npt2a as a target for treating hyperphosphatemia.Biochemical Society transactions · 2022
    Review
  8. Frontiers in endocrinology · 2021
    Article
  9. Research Models for Studying Vascular Calcification.International journal of molecular sciences · 2020
    Review
  10. Review
  11. Mechanisms of phosphate transport.Nature reviews. Nephrology · 2019
    Review
  12. FGF23 Synthesis and Activity.Current molecular biology reports · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Systemic Control of Bone Homeostasis by FGF23 Signaling.Current molecular biology reports · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shoji IchikawaDepartments of Medicine (S.I., A.K.G., L.R.P., N.M.S., M.J.E.), Anatomy and Cell Biology (M.R.A.), and Medical and Molecular Genetics (E.L.C., K.E.W., M.J.E), Indiana University School of Medicine, Indianapolis, Indiana 46202.
Amie K Gray
Leah R Padgett
Matthew R Allen
Erica L Clinkenbeard
Nicole M Sarpa
Kenneth E White
Michael J Econs
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

CLINICAL AND GENETIC ANALYSIS OF ADHRR01AR042228 · NIAMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI ECONS, MICHAEL J · 1999 to 2014
$4.3M
FGF-23 REGULATION OF PHOSPHATE HOMEOSTASISR01DK063934 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI WHITE, KENNETH E · 2003 to 2015
$3.8M
Indiana Clinical and Translational Science Institute-K12 ProgramKL2RR025760 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$2.2M
Control of FGF23 Bioactivity via Circulating alpha-KlothoR01DK095784 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2013 to 2017
$1.7M
SkyScan 1172 High-resolution desk-top micro-CT systemS10RR023710 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI WILLIAMS, JAMES C · 2007 to 2007
$297k
NCRR NIH HHS KL2 RR025760NCRR NIH HHS S10 RR023710NCRR NIH HHS S10-RR023710NIAMS NIH HHS R01 AR042228NIDDK NIH HHS DK063934NIDDK NIH HHS DK095784NIDDK NIH HHS R01 DK063934NIDDK NIH HHS R01 DK095784
6 · The paper itself

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone that inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D biosynthesis. The FGF23 subtilisin-like proprotein convertase recognition sequence ((176)RHTR(179)↓) is protected by O-glycosylation through ppGalNAc-T3 (GALNT3) activity. Thus, inactivating GALNT3 mutations render FGF23 susceptible to proteolysis, thereby reducing circulating intact hormone levels and leading to hyperphosphatemic familial tumoral calcinosis. To further delineate the role of glycosylation in the Fgf23 function, we generated an inducible FGF23 transgenic mouse expressing human mutant FGF23 (R176Q and R179Q) found in patients with autosomal dominant hypophosphatemic rickets (ADHR) and bred this animal to Galnt3 knockout mice, a model of familial tumoral calcinosis. Due to the low intact Fgf23 level, Galnt3 knockout mice with wild-type Fgf23 alleles were hyperphosphatemic. In contrast, carriers of the mutant FGF23 transgene, regardless of Galnt3 mutation status, had significantly higher serum intact FGF23, resulting in severe hypophosphatemia. Importantly, serum phosphorus and FGF23 were comparable between transgenic mice with or without normal Galnt3 alleles. To determine whether the presence of the ADHR mutation could improve biochemical and skeletal abnormalities in Galnt3-null mice, these mice were also mated to Fgf23 knock-in mice, carrying heterozygous or homozygous R176Q ADHR Fgf23 mutations. The knock-in mice with functional Galnt3 had normal Fgf23 but were slightly hypophosphatemic. The stabilized Fgf23 ADHR allele reversed the Galnt3-null phenotype and normalized total Fgf23, serum phosphorus, and bone Fgf23 mRNA. However, the skeletal phenotype was unaffected. In summary, these data demonstrate that O-glycosylation by ppGaINAc-T3 is only necessary for proper secretion of intact Fgf23 and, once secreted, does not affect Fgf23 function. Furthermore, the more stable Fgf23 ADHR mutant protein could normalize serum phosphorus in Galnt3 knockout mice.

Indexed as

Amino Acid SubstitutionAnimalsDisease Models, AnimalFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic TherapyGlycosylationMaleMiceMice, Inbred C3HMice, Inbred C57BLMice, KnockoutN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferase

Identifiers

PMID25051439
PMCPMC4164931
OpenAlexW1978896465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.